Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "R/R diffuse large B-cell Lymphoma"

AbbVie's Phase III EPCORE DLBCL-1 Trial Shows PFS Benefit With Epcoritamab in Relapsed/Refractory DLBCL

$AbbVie's Phase III EPCORE DLBCL-1 Trial Shows PFS Benefit With Epcoritamab in Relapsed/Refractory DLBCL$

AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.

R/R Diffuse Large B-cell Lymphoma | 19/01/2026 | By News Bureau | 170

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members